Solid Biosciences Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) Insider Trading Arrangements
The following table describes, for the third quarter of 2026, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
| Name (Title) | Action Taken (Date of Action) | Type of Trading Arrangement | Nature of Trading Arrangement | Duration of Trading Arrangement | Aggregate Number of Securities |
|---|---|---|---|---|---|
| Sukumar Nagendran, M.D. (Director) | Adoption (June 30, 2026)(1) | Rule 10b5-1 trading arrangement | Sale, including sales of shares to be acquired upon exercise of stock options | Until June 30, 2027, or such earlier date upon which all transactions are completed or expire without execution | Up to 177,700 shares of common stock |
(1) Countersigned by the broker on July 24, 2026.
Item 6. Ex
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.